期刊文献+

c-erbB-2的表达与非小细胞肺癌多药耐药的关系 被引量:4

Relationship betweent expession of c-erbB-2 and multidrug resistance in non-small cell lung cancer
下载PDF
导出
摘要 目的探讨c-erbB-2基因表达和非小细胞肺癌的化疗耐药性的关系,初步明确c-erbB-2基因在介导非小细胞肺癌(NSCLC)耐药机制中的作用。方法应用MTT法对54例未经化疗的非小细胞肺癌进行体外化疗药物敏感性测试,观察非小细胞肺癌分别对环磷酰胺、阿霉素、顺铂+氟尿嘧啶三种单药和联合用药方案耐药情况;用免疫组织化学方法检测c-erbB-2基因的表达,并对其表达情况与对应的化疗耐药性进行相关分析。结果54例NSCLC化疗敏感性检测结果显示:32例(59.3%)对环磷酰胺耐药,31例(57.4%)对阿霉素耐药,25例(46.3%)对顺铂+氟尿嘧啶耐药。其中,11例(20.4%)对3种用药均敏感,16例(29.6%)对3种用药均耐药,其耐药性与组织学类型和分化程度无关(P>0.05)。c-erbB-2在54例非小细胞肺癌中总的阳性表达率为53.7%,其中鳞癌和腺癌相比c-erbB-2的表达无显著性差异(P>0.05)。c-erbB-2的表达与3种化疗用药的耐药性均呈显著正相关(P<0.05),并且不同表达程度间也有显著差异性(P<0.05)。结论c-erbB-2在非小细胞肺癌中有较高的阳性表达,其参与介导了NSCLC固有化疗耐药的机制。 Objective To investigate the relationship between the expression of c-erbB-2 and multidrug resisance (MDR) for chemotherapy in non- small cell lung cancer( NSCLC), and define the function of the c-erbB-2 gene in MDR mechanisrns. Methods Forty NSCLC patients were tasted with MTT as,say to evaluate their chernoresistance. The chemotherapy drugs include cyclopharnide, adriamycin, and eisplatin plus fluorouracil. The expression of the c-erbB-2 gene was examined with irnrnunohistochernical assay. Results The MDR percentage for cyclophamide, adriamycin, and cisplatin plus fluorouracil were 59.3 %, 57.4 %, and 46.3 %, respectively. There was 16 cases resisting all three medications, while there was 11 cases sensitizing for all three medications. The MDR was not associated with histological types and degree of differentiation of NSCLC . The expression percentage of the c-erbB-2 in NSCLC was 53.7%. There is not significant difference in the expression of c- erbB-2 between adeoncarcinorna and sequamous cell arcinorna( P 〉0.05 ). The expression of c-erbB-2 had a parallel relationship with the degrees of ehernoresistance in three kinds of agents (P 〈 0.05 ), and the MDR degrees in three kinds of agents among the different degrees of expressions of c-erbB-2 were significantly different (P 〈 0.05). Conclusion A higher positive expresion of c-erbB-2 is present in NSCLC patients, and the expresion of e-erbB-2 participates in the intrinsic MDR in NSCLC patients.
出处 《新乡医学院学报》 CAS 2006年第5期469-472,共4页 Journal of Xinxiang Medical University
关键词 非小细胞肺痈 多约耐药 C-ERBB-2基因 体外药敏试验 免疫绀织化学 non-small lung cancer multidrug resistance c-erbB-2 gene chemc,sensitivity assay in vitro immunohisto-chemisty
  • 相关文献

参考文献7

二级参考文献26

  • 1李西平,刘叙仪,王洁,王曾礼,蒋薇,张毅,刘元林.反应停对人肺腺癌亲代及耐顺铂细胞系碱性成纤维细胞生长因子表达影响[J].中国呼吸与危重监护杂志,2003,2(1):40-43. 被引量:3
  • 2辛华雯,王润帮.MTT显色法快速测定实体瘤化疗药物敏感性的方法研究[J].肿瘤防治研究,1993,20(4):254-256. 被引量:26
  • 3张迺蘅.医学分子生物学[M].北京:北京医科大学出版社,1999.577-644.
  • 4Kerbel RS.Tumor angiogenesis:past,present and the near future.Carcinogenesis,2000;21:505~515
  • 5Slodkowska J,Sikora J,Roszkowski-Sliz K,et al.Expression of vascular endothelial growth factor and basic fibroblast growth factor receptors in lung cancer.Anal Quant Cytol Histol,2000;22:398~402
  • 6Volm M,Koomagi R,Mattern J.PD-ECGF,bFGF,and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis.Anticancer Res,1999;19:651~656
  • 7Stavrovskaya AA.Cellular mechanisms of multidrug resistance of tumor cells.Biochemistry (Mosc),2000;65:95~106
  • 8Kuwano M,Toh S,Uchiumi T,et al.Multidrug resistance-associated protein subfamily transporters and drug resistance.Anticaner Drug Des,1999;14:123~131
  • 9Martin F,Gudrun P,Thomas S,et al.Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia.Blood,1998;91:1508~1513
  • 10Yu D,Liu B,Jing T,et al.Overexpression of both p185 c-erbB 2 and p170 mdr-1 renders breast cancer cells highly resistant to taxol.Oncogene,1998;16:2087~2094

共引文献101

同被引文献20

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部